Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia–Reperfusion Injury via the TLR4/MyD88/NF‐κB p65 Pathway in Rats
- 4 September 2025
- journal article
- Published by Wiley in Phytotherapy Research
- Vol. 39 (10) , 4744-4765
Abstract
Background and aim Our previous study confirmed that ASIV can protect the lung from ischemia–reperfusion injury. The aim of this study was to determine whether ASIV attenuates PIRI by inhibiting the activation of the TLR4/MyD88/NF‐κBp65 pathway. Experimental procedure In vitro, the protection of ASIV, TAK‐242, NAC, and DEX to OGD/R‐induced cell injury was compared. In vivo, the PIRI model was induced in SD rats. The lung tissue W/D ratio and pathological morphology, as well as the markers of oxidative stress, were monitored. The mRNA and protein expression levels correlated to the TLR4/MyD88/NF‐κB p65 pathway were evaluated. Furthermore, we performed molecular docking and binding affinity calculations of the interaction between ASIV and TLR4‐MD‐2, which was verified with SPR. Key results and conclusions and implications ASIV showed more effective protection than DEX or NAC, and exhibited a synergistic effect with TAK‐242. After treatment with ASIV, lung tissue and cellular damage were obviously alleviated, and the levels of T‐SOD and GSH‐PX were significantly increased, while lung MDA and MPO decreased. Moreover, the ASIV groups showed a significant down‐regulation of the TLR4, MyD88, NF‐κBp65 and p‐NF‐κBp65 proteins when compared with the PIRI model group. The prediction showed that ASIV can enter the cavity of TLR4‐MD‐2 and exhibit strong binding, with a free binding energy of −8.0 kcal·mol−1. SPR further confirmed that ASIV rapidly bound to the rhTLR4‐MD‐2 complex with a KD of 2.17 × 10−6 M. In conclusion, ASIV can specifically bind to rhTLR4‐MD‐2, thus alleviating PIRI by suppressing the activation of the TLR4/MyD88/NF‐κB65‐mediated inflammatory pathway.Keywords
Funding Information
- National Natural Science Foundation of China (82173866)
This publication has 51 references indexed in Scilit:
- Astragaloside IV ameliorates radiation‐induced nerve cell damage by activating the BDNF/TrkB signaling pathwayPhytotherapy Research, 2023
- Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathwayInternational Immunopharmacology, 2021
- Protective effects of naringin and trimetazidine on remote effect of acute renal injury on oxidative stress and myocardial injury through Nrf-2 regulationPharmacological Reports, 2019
- Differential toll-like receptor activation in lung ischemia reperfusion injuryThe Journal of Thoracic and Cardiovascular Surgery, 2015
- Role of Toll-Like Receptor-4 in Lung Ischemia-Reperfusion InjuryThe Annals of Thoracic Surgery, 2015
- Astragaloside IV Attenuates Injury Caused by Myocardial Ischemia/Reperfusion in Rats via Regulation of Toll‐Like Receptor 4/Nuclear Factor‐κB Signaling PathwayPhytotherapy Research, 2015
- The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseasesInternational Immunopharmacology, 2011
- Toll-Like Receptor 4 Mediates Lung Ischemia-Reperfusion InjuryThe Annals of Thoracic Surgery, 2006
- TLR signalling and activation of IRFs: revisiting old friends from the NF-κB pathwayTrends in Immunology, 2005
- Inhibition of nuclear factor κB by IκB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2005